Abbott and Galapagos Announce Collaboration for Novel Oral Therapy
February 29, 2012 – Abbott and Galapagos have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases.
Document Actions
